The aim of this study is to assess the effect of genistein supplementation on inflammatory and oxidative indices and lipid profile in non alcoholic fatty liver patients. This randomized, double-blind, placebo-controlled will be single center study. This study is in phase 3 of clinical trial. Inclusion criteria: adult volunteers between 18 and 70 whom their fatty liver were confirmed by ultrasonography and don't have any Acute or chronic disease of the liver or bile ducts will be recruited. Exclusion criteria: severe weight loss or gain, pregnancy, ALT serum level 10 times more than normal range during study. Patients will receive 250 mg genistein or placebo once a day for 8 weeks. Patients will have a pre and post treatment laboratory evaluation including measurements of serum AST, ALT, TNF-α, IL-6, triglyceride, total cholesterol, LDL, HDL and amount of hepatic steatosis (by fibroscan), waist circumference, weight and height.